Novavax, Inc. (NASDAQ:NVAX)

CAPS Rating: 1 out of 5

A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.

Recs

0
Player Avatar WF2005 (41.89) Submitted: 8/21/2009 11:40:43 AM : Underperform Start Price: $4.71 NVAX Score: +102.11

because UltraLong thinks so

Report this Post Reply

Featured Broker Partners


Advertisement